feedback

Course Director

Omid Hamid, MD
Omid Hamid, MD

The Angeles Clinic and Research Institute
Samuel Oschin Cancer Center
Cedars Sinai Medical Care Foundation
Los Angeles, California

Faculty

Edward B. Garon
Edward B. Garon, MD, MS

UCLA's Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Naiyer Rizvi
Naiyer Rizvi, MD

Columbia University Medical Center
New York, New York

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2016-May-24
Expiration Date:2017-May-23
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

A live dinner symposium on the future directions of immunotherapy in cancer, with a focus on immune checkpoint inhibitors, took place on Saturday, April 16, 2016, at the Sheraton New Orleans Hotel.

Advances in therapeutic targeting of immune response mechanisms in cancer have established a role for checkpoint-blocking agents in settings such as melanoma and lung cancer. However, new evidence suggests that checkpoint blockade may have a therapeutic role in other tumor settings, and that newer immuno-oncology combinations may advance the field of immunotherapy as a whole and offer more potent immune-based treatment in several different cancers. During the symposium, a panel of expert clinicians offered their views on the science that has led to the emergence of immune checkpoint blockade and sparked interest in novel immunotherapy combinations; assessed the ongoing search for biomarkers and the challenges associated with their use; and provided important analyses of clinical evidence on checkpoint blockade in tumor settings where immunotherapies have yet to be validated. The meeting ended with a chance for attendees to participate in a question and answer session with the faculty panel.

Upon completion of this activity, participants should be better able to:

  • Cite the mechanisms of checkpoint blocking immunotherapies in cancer, including strategies targeting PD-1/PD-L1, among others
  • Assess early evidence on the clinical potential of biomarkers for checkpoint blocking agents in the cancer setting
  • Summarize recent safety and efficacy evidence on the use of new and emerging immuno-oncology strategies across several solid tumor and hematologic cancer settings
  • Describe novel immuno-oncology strategies, including biomarker-driven treatment and combination approaches, being tested in ongoing clinical trials in a range of solid tumor and hematologic cancer settings

Target Audience

This activity has been designed to meet the educational needs of cancer research scientists, oncologists, and other healthcare professionals involved in the care of patients with cancer who may be eligible for treatment with novel immunotherapy.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: May 24, 2016 - May 23, 2017
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity for any amount during the past 12 months.

Course Director and Moderator

Omid Hamid, MD
Chief, Translational Research & Immuno-Oncology – The Angeles Clinic and Research Institute
Co-Director, Melanoma Program – Samuel Oschin Cancer Center
Director, Experimental Therapeutics – Cedars Sinai Medical Care Foundation
Los Angeles, California

Omid Hamid, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd.; and Novartis Pharmaceuticals Corporation.
Speakers Bureau participant with Bristol-Myers Squibb; Genentech, Inc.; and Novartis Pharmaceuticals Corporation.

Omid Hamid, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: PD-1/PD-L1 checkpoint inhibitors and other novel immunotherapeutic agents in development for the treatment of solid tumors and hematologic cancers.

Faculty

Edward B. Garon, MD, MS
Health Sciences Associate Professor
Department of Medicine, Division of Hematology-Oncology
UCLA's Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Edward B. Garon, MD, MS, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Merck & Co.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Edward B. Garon, MD, MS, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: PD-1/PD-L1 checkpoint inhibitors and other novel immunotherapeutic agents in development for the treatment of solid tumors and hematologic cancers.

Naiyer Rizvi, MD
Professor of Medicine
Director of Thoracic Oncology and Phase I Immunotherapeutics
Columbia University Medical Center
New York, New York

Naiyer Rizvi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd; and Novartis Pharmaceuticals Corporation.
Shareholder in Gritstone Oncology where Dr. Rizvi is a Co-Founder.

Naiyer Rizvi, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: PD-1/PD-L1 checkpoint inhibitors and other novel immunotherapeutic agents in development for the treatment of solid tumors and hematologic cancers.

CME Reviewer

Vijaya R. Bhatt, MD
University of Nebraska Medical Center
Omaha, Nebraska

Vijaya R. Bhatt, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Merck & Co., Inc., Incyte Corporation and Genentech.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.